Dr Peter Lau
Dr Peter Lau is an immuno-oncologist at Linear Clinical Research and has been a WAKMAS panel member since 2020. Previously Peter was a medical oncologist in the melanoma and skin service at Peter MacCallum Cancer Centre from 2016. During this time, he was engaged in both clinical and laboratory based research in melanoma and immunotherapy. Peter is one of the lead investigators for the CHARLI clinical trial which is an Australian multi-centre study that investigates the addition of denosumab to immune checkpoint inhibitors such as nivolumab and ipilimumab-nivolumab. He also has interests in immunotherapy toxicity and serves on the eviQ melanoma reference committee for melanoma and management of immune related adverse events since 2014. With over 20 peer reviewed publications in journals including the European Journal of Cancer, Cancer Research and Journal of Immunotherapy for Cancer brings a wealth of experience of immunotherapy to Perth.